Warning letter
Bell International Laboratories, Inc.: warning letter of Feb 15, 2024
FDA warning letter 669736 · Division of Pharmaceutical Quality Operations III
Key facts
| Reference number | 669736 |
|---|---|
| Company | Bell International Laboratories, Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 15, 2024 |
| Posted date | Mar 5, 2024 |
| Issuing office | Division of Pharmaceutical Quality Operations III |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.188, 211.192, 211.22(a), 211.84(d)(1), 211.198(a), 211.100(a) |
| Inspection city | Eagan |
| Inspection ZIP | 55121 |
| Inspection start date | Sep 11, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: